Meeting
2021 Gastrointestinal Cancers Symposium
Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) U.S. patients (pts) with advanced HCC (aHCC).
Authors
Xiaoliang Wang
Flatiron Health, New York, NY
Xiaoliang Wang , Kelly Magee , Anala Gossai , Christina M. Parrinello , Rebecca A. Miksad , Richard D. Kim , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 341)
DOI
10.1200/JCO.2021.39.3_suppl.341
Abstract #
341
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration.
First Author: Munaf Alkadimi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
First Author: Gregory Naylor
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.
First Author: Jagpreet Chhatwal
Poster
2020 Gastrointestinal Cancers Symposium
Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.
First Author: Peter R. Galle